Boehringer Ingelheim Corporation

Type: Company
Name: Boehringer Ingelheim Corporation
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Boehringer Ingelheim Launches OFEV (nintedanib) in U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that OFEV (nintedanib) capsules are now commercially available in the United States. According to a release from the Company, OFEV was approved by the U.S. Food and Drug Administration (FDA) on ... [Published Individual.com - Oct 23 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Boehringer Ingelheim's OFEV Approved by FDA as a Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration (FDA) approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).According to a release from the Company, granted ... [Published Individual.com - Oct 20 2014]
First reported Oct 16 2014 - Updated Oct 17 2014 - 1 reports

FDA Approves Boehringer Ingelheim’s IPF Treatment

- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved OFEV® (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). Granted Breakthrough Therapy designation ... [Published Noodls - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Boehringer Ingelheim Corporation And Partner To Expand Product Donations Program Globally

RIDGEFIELD, Conn.--(BUSINESS WIRE)--Boehringer Ingelheim Cares Foundation announced today it is providing a free supply of hypertension medicines to approximately 140 patients in Santiago de Maria, El Salvador. The donation is an expansion of its Product ... [Published BioSpace - Oct 15 2014]
First reported Oct 08 2014 - Updated Oct 09 2014 - 1 reports

New COPD Maintenance Treatment Striverdi® Respimat® (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies

RIDGEFIELD, Conn. , Oct. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States . STRIVERDI RESPIMAT is a long-term, ... [Published CEOWorld Magazine - Oct 08 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

Boehringer Ingelheim Corporation To Create 100 New Jobs With $125 Million+ Site Expansion

German research-driven pharmaceutical firm Boehringer Ingelheim is investing more than €100m at its Dortmund site to increase the production capacity of Respimat inhaler to 44 million units per year.The expansion is expected to help the pharmaceutical ... [Published BioSpace - Oct 01 2014]
First reported Sep 26 2014 - Updated Sep 27 2014 - 1 reports

Boehringer Ingelheim Corporation Release: Nintedanib* Receives Positive CHMP Opinion For Second-Line Treatment Of Patients With Adenocarcinoma Of The Lung

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of nintedanib* (suggested brand name Vargatef®) in combination with ... [Published BioSpace - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Boehringer Ingelheim Statement on FDA Drug Development Public Meeting for Idiopathic Pulmonary Fibrosis (IPF)

RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S. Food and Drug Administration (FDA) for conducting today's public meeting to better understand the daily experiences of those living with idiopathic pulmonary fibrosis ... [Published Scottrade - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

FDA Approves Spiriva Respimat (tiotropium) for the Maintenance Treatment of COPD

Patients using Spiriva will now have a choice between a mist and a dry powder inhaler.Ridgefield, Conn., September 25, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva ... [Published Drugs.com - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Boehringer Ingelheim Corporation Plans To Cut Up To 600 Jobs

(Reuters) - Drugmaker Boehringer Ingelheim said it plans to cut up to 600 jobs in Germany, citing healthcare budget cuts in the United States and a stricter reimbursement regime in Germany.The unlisted family-controlled group, which collaborates on diabetes ... [Published BioSpace - Sep 23 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

US FDA approves Jardiance tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced the US Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose ... [Published PharmaBiz - Aug 05 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

CHMP recommends Lilly/Boehringer's new insulin glargine product for approval in EU to treat type 1 and type 2 diabete

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine ... [Published PharmaBiz - Jun 30 2014]

Quotes

...with OFEV," said Tunde Otulana, M D , a pulmonologist and senior vice president, Clinical Development and Medical Affairs at Boehringer Ingelheim. "Bringing a new treatment such as OFEV to patients when there is such significant unmet need is the result of many years of research and demonstrates our commitment to making a difference for patients with respiratory diseases."
...52 weeks," said Tunde Otulana, M D , a pulmonologist and senior vice president, Clinical Development and Medical Affairs at Boehringer Ingelheim. "As a research-driven pharmaceutical company, moments like these, when we can bring a treatment option to patients who are very much in need, makes us extremely proud and inspires us to continue our quest for effective therapies to positively impact patients' lives."
...as a new COPD maintenance treatment option," said Kathleen M Dowd , senior vice president, Marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe STRIVERDI RESPIMAT will be a welcome option for providers and patients alike."
Boehringer Ingelheim member of the Board of Managing Directors Dr Wolfgang Baiker said: "The Respimat inhaler will also in future be the inhalation device for applying our respiratory medications."

More Content

All (17) | News (17) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Boehringer Ingelheim Launches OFEV (nintedanib)... [Published Individual.com - Oct 23 2014]
Boehringer Ingelheim's OFEV Approved by FDA as ... [Published Individual.com - Oct 20 2014]
FDA Approves Boehringer Ingelheim’s IPF Treatment [Published Noodls - Oct 16 2014]
Boehringer Ingelheim Corporation And Partner To... [Published BioSpace - Oct 15 2014]
New COPD Maintenance Treatment Striverdi® Respi... [Published CEOWorld Magazine - Oct 08 2014]
Boehringer Ingelheim Corporation To Create 100 ... [Published BioSpace - Oct 01 2014]
Boehringer Ingelheim Statement on FDA Drug Deve... [Published Scottrade - Sep 26 2014]
Boehringer Ingelheim Corporation Release: Ninte... [Published BioSpace - Sep 26 2014]
FDA Approves Spiriva Respimat (tiotropium) for ... [Published Drugs.com - Sep 26 2014]
Boehringer Ingelheim Corporation Plans To Cut U... [Published BioSpace - Sep 23 2014]
US FDA approves Jardiance tablets for adults wi... [Published PharmaBiz - Aug 05 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
Boehringer Ingelheim, Lilly resubmit SGLT2 inhi... [Published PharmaBiz - Jun 19 2014]
Two phase III trials of empagliflozin/linaglipt... [Published PharmaBiz - Jun 17 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
EU recommends approval of empagliflozin to redu... [Published PharmaBiz - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.